Crinetics (CRNX) Director Nichols Weston Receives Awards

What Happened
Nichols Weston, a director of Crinetics Pharmaceuticals (CRNX), received two equity awards on 2026-06-18: 5,925 restricted stock units (RSUs) and 9,730 derivative awards (stock options), each reported at $0.00 (no cash paid). The Form 4 reports these as grants (transaction code A); the filing does not state a cash value or exercise price for the derivative award.

Key Details

• Transaction date: 2026-06-18; Form 4 filed: 2026-06-22 (filed within the SEC’s two-business-day window given the June 19 holiday/weekend).
• Awards: 5,925 RSUs (F1) and 9,730 derivative awards (stock option-type award; F2), both reported at $0.00.
• Vesting: RSUs vest 100% on the earlier of (a) the first anniversary of the grant or (b) the next annual meeting of stockholders, subject to continued board service (F1). The derivative award vests/becomes exercisable on the same timing and service condition (F2).
• Shares owned after transaction: not specified in the provided excerpt.
• Transaction code: A = Award/Grant. No 10b5-1 plan or tax-withholding details reported in the excerpt.

Context
RSUs represent a right to receive shares upon vesting; stock options give the right to purchase shares after vesting. These are compensation grants to a director and are routine governance/compensation activity rather than an open-market purchase or sale. They do not by themselves indicate immediate buying or selling of stock.